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T
ype 1 diabetes is a disorder caused by the
autoimmune-mediated destruction of insulin-
producing -cells in the pancreas (1). Many
promising intervention trials are currently un-
derway or in development to prevent -cell loss in patients
with recent-onset type 1 diabetes and in individuals at
increased risk for type 1 diabetes due to the presence of
autoantibodies or elevated genetic risk (2). Despite this
hope for future interventions, islet transplantation remains
the only therapeutic option currently available for individ-
uals with established type 1 diabetes when insulin therapy
fails to maintain adequate metabolic control (3). Islet
allograft transplantation has demonstrated great success
in terms of restoring normoglycemia (4). Unfortunately,
the long-term efﬁcacy following transplantation has been
limited due to chronic graft rejection (5). Thus, an optimal
approach would involve an islet transplantation protocol
that would prevent graft rejection without the need for
potentially dangerous long-term and nonspeciﬁc immune
suppression.
Mesenchymal stem cells (MSCs) have been proposed to
be one possible means to enhance current islet transplan-
tation protocols (6). MSCs represent a population of
nonhematopoetic precursor cells that have generated
marked interest and attention for their capacity to elicit
tissue regeneration (7–9). For the treatment of type 1
diabetes, the therapeutic potential of MSCs is potentially
twofold. First, these cells are reported to provide critical
growth factors for tissue regeneration (8). Second, these
cells possess potent immunoregulatory properties that
could be exploited to suppress allograph rejection follow-
ing transplantation (6).
In this issue of Diabetes, Ding et al. (10) provide
evidence that MSCs possess the capacity to impede T-cell
activation both in the context of a delayed-type hypersen-
sitivity reaction and following an islet allotransplantation
protocol. The authors essentially accomplished this
through a series of in vitro and in vivo studies suggesting
that MSCs exert potent immunosuppressive properties by
blocking the interleukin (IL)-2 cytokine signaling pathway
required for T-lymphocyte activation, expansion, and dif-
ferentiation (11,12).
Given the potent immunosuppressive properties of
MSCs, the authors of this article sought to interrogate the
potential mechanism(s) of suppression. A prior study had
implicated various immunomodulatory pathways in the
ability of MSCs to suppress T-cell responses. These in-
clude production of the immunomodulatory cytokines
TGF- and IL-10 (13) as well as enzymatic pathways
involving indolamine 2,3-dioxygenase (12), nitric oxide
synthase (14), and heme oxygenase-1 (15). Adding to the
existing literature, Ding et al. demonstrate the potent
immunosuppressive properties of MSCs in vitro either
when cocultured with polyclonal T-cells that are activated
with microbeads coated with anti-CD3 and anti-CD28 or
during allogeneic antigen stimulation. The authors noted
little inﬂuence on T-cell activation when the pathways
described previously were speciﬁcally targeted. On the
other hand, these authors did observe that production of
the enzymes matrix metalloproteinase (MMP)-2 and -9 by
MSCs had a potent immunosuppressive effect on T-cell
activation. This ﬁnding is analogous to that described
previously by Sheu et al. (16), who showed that MMP-2
and -9 production by tumors is capable of creating an
immunosuppressive microenvironment. The authors also
showed that the mechanism of suppression of T-cell activa-
tion involved the speciﬁc cleavage of CD25 (the -chain of
the IL-2 receptor) from the surface of responding CD4

T-cells (see Fig. 1).
How can the ﬁndings by Ding et al. be translated into the
clinic to beneﬁt patients with type 1 diabetes? Whereas the
authors demonstrated the efﬁcacy of MSCs in suppressing
a delayed-type hypersensitivity response and in preventing
rejection of an islet allograft, additional studies are clearly
warranted in animal models that more closely approxi-
mate clinical treatments in humans. Speciﬁcally, it will be
helpful for future studies to test the capacity of MSCs to
prevent allograft rejection in nonimmunodeﬁcient recipi-
ent hosts (i.e., the authors reconstituted immunodeﬁcient
BALB/c Rag
/
/ mice with naïve BALB/c CD4
CD25

T-cells and transplanted B6 islets in the presence or
absence of BALB/c MSCs). Moreover, it will be informative
to assess the site of action for MSCs. Are MSCs simply
guarding the border of the transplanted tissue to create a
local immunosuppressive milieu, or is there a long-term
tolerogenic effect of MSCs in the draining lymph nodes of
the target organ, presumably the site where the majority of
antigen priming occurs? Finally, it is of interest whether
MSCs will show efﬁcacy in blocking recurrent autoimmu-
nity and preventing allograft rejection, with the former
presumably a more difﬁcult response to impede because
memory T-cell responses may be less dependent on IL-2
signaling for effector function (16). One could also specu-
late that the cleavage of CD25 from the surface of regula-
tory T-cells (a population of cells characterized as IL-2
dependent and constitutively CD25
) might be detrimental
in some settings (17,18). These questions are critical for
understanding the mechanism(s) of action of MSCs and in
the future design of translational therapies.
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1728 DIABETES, VOL. 58, AUGUST 2009From a broader immune standpoint, questions remain
regarding the immunomodulatory properties of MMP-2
and -9. These proteolytic enzymes are produced not only
by MSCs (as highlighted in this issue) but also by innate
antigen-presenting cells as well as in an autocrine fashion
by T-cells following activation (reviewed in 19). Their role
in modulating the normal immune response remains
poorly deﬁned and requires additional consideration.
This study brings to light a novel mechanism by which
MSCs can protect transplanted tissues and raises the
possibility that these cells could be added to current
protocols to improve the long-term engraftment of trans-
planted islets. Clearly, more studies in animal models are
required to validate these results and further describe the
therapeutic mechanisms of MSCs.
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FIG. 1. MSCs protect transplanted alloge-
neic islets by creating an immunosuppres-
sive microenvironment. MMP-2 and -9
produced by MSCs suppress T-cell re-
sponses by cleaving the high-afﬁnity
growth factor receptor CD25 (the -chain
of the IL-2 receptor) from the surface of
inﬁltrating T-lymphocytes.
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